

A comparative effectiveness cohort study of biosimilar pegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplantation

Electronic Supplementary Material

Authors: Massimo Martino, Mercedes Gori, Gaetana Porto, Maria Pellicano, Chiara Verduci, Filippo Antonio Canale, Barbara Loteta, Tiziana Moscato, Caterina Alati, Maria Consuelo Ieracitano, Amelia Cuzzocrea, Maria Altomonte, Maria Teresa Florenzano, Antonella Morabito, Giuseppe Irrera, Virginia Naso, Marta Pugliese, Giuseppe Console, Anna Ferreri, Lucrezia Imbalzano, Giovanni Tripepi, Annalisa Pitino

Corresponding author: Massimo Martino MD, Stem Cell Transplantation and Cellular Therapies Unit (CTMO) Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy. **Email:** massimo.martino@ospedalerc.it

Table S1 Restricted mean survival time (RMST) estimates and Δ RMST of univariate and multiple models within 13 days

		RMST (95% CI)	ΔRMST diff (95% CI)	p-value
Treatments	Time window	<i>Univariate analyses</i>		
BIO/G-CSF	13 days	11.03 (10.89–11.17)	1.03 (0.72–1.34)	<0.001
BIO/PEG	13 days	10.00 (9.73–10.27)	–	
BIO/G-CSF	13 days	11.03 (10.89–11.17)	1.28 (0.98–1.58)	<0.001
PEG	13 days	9.75 (9.49–10.02)	–	
PEG	13 days	9.75 (9.49–10.02)	-0.25 (-0.63–0.13)	0.2
BIO/PEG	13 days	10.00 (9.73–10.27)	–	
<i>Age and sex adjusted analyses</i>				
Treatments	Time window	Between-group difference in RMST		
BIO/G-CSF vs. BIO/PEG	13 days	1.04 (0.74–1.34)		<0.001
BIO/G-CSF vs. PEG	13 days	1.31 (1.01–1.62)		<0.001
PEG vs. BIO/PEG	13 days	-0.26 (-0.65–0.12)		0.18

BIO/G-CSF, biosimilar granulocyte colony-stimulating factor (filgrastim-sndz); *BIO/PEG*, biosimilar pegfilgrastim (pegfilgrastim-bmez); *CI*, confidence interval; *diff*, difference; *PEG*, pegfilgrastim; *RMST*, restricted mean survival time